In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding
- PMID: 35099999
- DOI: 10.7326/J21-0014
In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding
Abstract
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. 34449183.
Comment on
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical